• Surgery Partners, Inc. recently reported first-quarter 2026 results, with revenue rising to US$810.9 million from US$776.0 million a year earlier and net loss narrowing to US$35.9 million, while reaffirming full-year 2026 revenue guidance of US$3.35 billion to US$3.45 billion.
• Beneath the headline loss, the company delivered a smaller-than-expected adjusted loss per share and 4.4% same-facility revenue growth, highlighting underlying volume and pricing momentum despite higher costs and a sizeable US$3.70 billion debt load.
• We’ll now examine how this combination of guidance reaffirmation and better-than-expected adjusted earnings shapes Surgery Partners’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Surgery Partners Investment Narrative Recap

To own Surgery Partners, you need to believe outpatient surgery volumes and higher‑acuity cases can support steady revenue growth while the company works its way through persistent losses and a sizeable US$3.70 billion debt load. In the near term, the key catalyst is management delivering on its 2026 revenue and EBITDA targets, while the biggest risk is pressure from interest costs and margins. The latest quarter, with guidance reaffirmed and a smaller adjusted loss, does not materially change that balance.

The reaffirmed 2026 revenue guidance of US$3.35 billion to US$3.45 billion is the announcement that ties most directly to this earnings print. It keeps the focus squarely on execution: turning 4.4% same‑facility revenue growth into better profitability, while managing higher costs and ongoing portfolio optimization and M&A efforts. For investors, the test is whether the company can hit those guidance numbers without further strain on margins or balance sheet flexibility.

Yet beneath the reaffirmed guidance, investors should still pay close attention to how interest costs and high leverage could...

Surgery Partners' narrative projects $3.9 billion revenue and $45.5 million earnings by 2029.

Uncover how Surgery Partners' forecasts yield a $18.80 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue of about US$4.2 billion and positive earnings by 2029, which is far more upbeat than consensus. When you compare that to the latest quarter and ongoing cost and debt concerns, you can see how views can differ widely, and this report may push those forecasts in either direction as the story around margin pressure and industry consolidation evolves.

Explore 2 other fair value estimates on Surgery Partners - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Surgery Partners research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.